INmune Bio is an early stage pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co.'s proprietary is to focus on the innate immune system that include natural killer cells (NK cells), myeloid derived suppressor cells (MDSC cells) and dendritic cells. Co.'s existing drug platforms are: INKmune which primes NK cells and INB03 which down regulates MDSC cells. The INMB stock yearly return is shown above.
The yearly return on the INMB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INMB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|